Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O94925

UPID:
GLSK_HUMAN

ALTERNATIVE NAMES:
K-glutaminase; L-glutamine amidohydrolase

ALTERNATIVE UPACC:
O94925; Q9UL05; Q9UL06; Q9UL07; Q9UN40

BACKGROUND:
The mitochondrial Glutaminase kidney isoform, with alternative names K-glutaminase and L-glutamine amidohydrolase, is essential for glutamine catabolism and acid-base balance. It controls brain glutamate, the primary excitatory neurotransmitter.

THERAPEUTIC SIGNIFICANCE:
Its association with conditions such as Developmental and epileptic encephalopathy 71 highlights its potential as a target for therapeutic intervention, especially in diseases marked by glutamate dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.